C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
195/1.235, 195/1
C12N 15/18 (2006.01) A61K 38/30 (2006.01) C07K 14/65 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2007886
Synthetic genes encoding two 70-amino acid analogs of human insulin-like growth factor (hIGF-I) have been constructed and expressed in the yeast, Saccharomyces cerevisiae. The protein analogs, IGF 150 and IGF 125 contain the first 17 amino acids of the A chain of human insulin in place of residues 42 to 58 of hIGF-I, and residues 8-10 of the A chain in place of residues 49 to 51 of hIGF-I, respectively. The purified proteins have high affinity for the human type I IGF receptor (3.2 and 7.0 nM respectively) yet have reduced relative affinity for the human and murine 28 K IGF binding proteins (7 fold and 45 fold, respectively). IGF 150 is 100 times more active than normal hIGF-I in stimulating DNA synthesis in 3T3 cells, and should be a more active growth factor in vivo due to its reduced affinity for 28 K IGF binding proteins. The protein analogs thus have a variety of utilities such as in promoting lactation in animals; promoting growth and feed efficiency in animals; improving carcass quality by increasing lean and decreasing fat; promoting wound healing in animals, including humans; promoting glucose utilization in skeletal muscle, and stimulating erythropoiesis, the production of red blood cells.
Bayne Marvin L.
Cascieri Margaret A.
Bayne Marvin L.
Cascieri Margaret A.
Goudreau Gage Dubuc
Merck & Co. Inc.
LandOfFree
Human insulin-like growth factor analogs with reduced... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human insulin-like growth factor analogs with reduced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human insulin-like growth factor analogs with reduced... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1690461